Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance
- PMID: 10626356
- DOI: 10.1016/s0162-0134(99)00144-0
Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance
Abstract
Several reports indicate that the mechanism of resistance to cisplatin is multifactorial. However, DNA damage tolerance appears to be the more significant mechanism. It is clear that resistance in general is a major clinical concern, and a number of approaches have been taken to circumvent this clinical impediment. One approach is through analog development, and we have identified 1,2-diaminocyclohexane-diacetatodichloro-platinum(IV) as an analog with activity in cisplatin resistance. The activity is greatest against ovarian tumor cell lines where the latent, non-inducible wild-type p53 function can be reactivated by the analog. This functional activation of p53 also corresponds to a reduced threshold for tolerance to DNA damage induced by the analog. Interestingly, cell lines with mutant or null p53 are cross-resistant to the analog. The data indicate that cisplatin resistance due to an increase in DNA damage tolerance can arise through a loss of p53 function, and that functional activation of latent wild-type p53 by the analog facilitates cell death and circumvents this resistance mechanism.
Similar articles
-
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).Clin Cancer Res. 1999 Mar;5(3):655-63. Clin Cancer Res. 1999. PMID: 10100719
-
Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.J Cancer Res Clin Oncol. 2003 Dec;129(12):709-18. doi: 10.1007/s00432-003-0480-4. Epub 2003 Sep 26. J Cancer Res Clin Oncol. 2003. PMID: 14513366
-
Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.Mol Cancer Res. 2017 Mar;15(3):328-339. doi: 10.1158/1541-7786.MCR-16-0257-T. Epub 2016 Dec 28. Mol Cancer Res. 2017. PMID: 28031409 Free PMC article.
-
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.J Inorg Biochem. 1999 Oct;77(1-2):111-5. J Inorg Biochem. 1999. PMID: 10626362 Review.
-
Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.Drug Resist Updat. 2005 Jun;8(3):131-46. doi: 10.1016/j.drup.2005.04.006. Drug Resist Updat. 2005. PMID: 15894512 Review.
Cited by
-
Recent developments in texaphyrin chemistry and drug discovery.Inorg Chem. 2013 Nov 4;52(21):12184-92. doi: 10.1021/ic400226g. Epub 2013 Apr 4. Inorg Chem. 2013. PMID: 23557113 Free PMC article. Review.
-
A texaphyrin-oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells.Medchemcomm. 2012;3(10):1275-1281. doi: 10.1039/C2MD20206A. Medchemcomm. 2012. PMID: 23936624 Free PMC article.
-
Role of copper transporters in platinum resistance.World J Clin Oncol. 2016 Feb 10;7(1):106-13. doi: 10.5306/wjco.v7.i1.106. World J Clin Oncol. 2016. PMID: 26862494 Free PMC article. Review.
-
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.Oncotarget. 2017 Feb 14;8(7):10905-10918. doi: 10.18632/oncotarget.14228. Oncotarget. 2017. PMID: 28038466 Free PMC article.
-
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.Biochem Pharmacol. 2012 Apr 15;83(8):1049-62. doi: 10.1016/j.bcp.2011.12.026. Epub 2011 Dec 26. Biochem Pharmacol. 2012. PMID: 22227014 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous